Oxford Immunotec Global PLC (NASDAQ: OXFD) began trading on the NASDAQ on 22 November 2013

U.K.-based Oxford Immunotec Global PLC (NASDAQ: OXFD) offered 5.4 million shares at $12, below the expected range of $13 to $15 a share on Friday. The company is a commercial-stage diagnostic test firm. Shares began trading at $14 and closed the day at $15.88.

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company. The Company’s T-SPOT technology platform allows the Company to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases. T cells are a central component of the human body’s immune system, and are implicated in the control and progression of many medical conditions, including certain types of infectious diseases, cancers and autoimmune diseases. The initial product it has developed using its T-SPOT technology platform is its T-SPOT.TB test, which is used to test for latent Tuberculosis (TB) infection (LTBI).

Address

94C Innovation Drive, Milton Park
ABINGDON, OX14 4RZ
United Kingdom 

Website links 

www.oxfordimmunotec.com